RxDoctor Payments Data

Jonathan Pender, NP

Acute Care · Richmond, VANPI 1285052720

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 75.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $10,191 and has fallen 92.0% since, to $813 in 2025. Among acute care clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,269in general payments, 2019–2025

Across 161 payments — averaging $82.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$10K
  • AbbVie$692
  • Sanofi$600
  • Regeneron Healthcare Solutions, Inc.$480
  • GSK$371
  • Alk-abello, Inc$190
  • plus $971 from 18 others
$2,315in research payments, 2019–2025

Across 8 payments — averaging $289.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$2K

What the payments were for

  • Speaking & faculty fees$6,44049%
  • Travel & lodging$3,03823%
  • Food & beverage$3,73128%
  • Education$600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,269 in reported general payments places this provider in the 95th percentile of 599 acute care providers in Virginia.

See all acute care providers in Virginia

Medicare billing

Part B allowed, 2024
$48,970
Medicare patients
294
Services billed
542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide92$3,031
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth20$1,819
Fluticasone Propionate72$953
Azelastine Hcl31$924
Ofloxacin29$815
Clarithromycin12$348
Fluocinolone Acetonide Oil13$323
Omeprazole44$315
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$217
Prednisone32$102
Doxycycline Hyclate15$92
Mupirocin27$91
Ciprofloxacin Hcl13$71

Paid to pharmacies, not to this prescriber.

Other acute care in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →